Genprex Inc.
| NASDAQ: GNPX | Healthcare / Biotechnology / USA |
| 0.9099 | +0.0069 | +0.76% | Vol 128.97K | 1Y Perf -60.04% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 0.8700 | ASK | 0.9297 | ||
| Open | 0.8900 | Previous Close | 0.9099 | ||
| Pre-Market | - | After-Market | 0.85 | ||
| - - | -0.06 -6.58% |
| Target Price | 5.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 449.51 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.00 | Earnings Rating | Neutral | |
| Market Cap | 47.29M | Earnings Date | 29th Mar 2023 | |
| Alpha | 0.10 | Standard Deviation | 0.78 | |
| Beta | -0.48 |
Today's Price Range 0.88250.9300 | 52W Range 0.73582.67 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.10% | ||
| 1 Month | -20.18% | ||
| 3 Months | -37.25% | ||
| 6 Months | -35.47% | ||
| 1 Year | -60.04% | ||
| 3 Years | -58.64% | ||
| 5 Years | -80.64% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -74.49 | |||
ROE last 12 Months | -62.37 | |||
ROA (5Y Avg) | -21.31 | |||
ROA last 12 Months | -59.41 | |||
ROC (5Y Avg) | -177.38 | |||
ROC last 12 Months | -62.47 | |||
Return on invested Capital Q | -20.40 | |||
Return on invested Capital Y | -13.15 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.00 | ||||
| 2.50 | ||||
| - | ||||
| - | ||||
| -5.20 | ||||
| -0.33 | ||||
| 2.56 | ||||
| 0.94 | ||||
| 43.16M | ||||
| Forward PE | -1.87 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.40 | ||||
| 10.70 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.13 | - |
| Q02 2022 | -0.10 | -0.11 | -10.00 |
| Q01 2022 | -0.09 | -0.12 | -33.33 |
| Q02 2020 | -0.19 | -0.12 | 36.84 |
| Q01 2020 | - | -0.20 | - |
| Q03 2019 | -0.22 | -0.15 | 31.82 |
| Q02 2019 | -0.21 | -0.24 | -14.29 |
| Q01 2019 | -0.23 | -0.14 | 39.13 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2022 QR | -0.12 | 0.00 | - |
| 12/2022 QR | -0.11 | 0.00 | - |
| 12/2022 FY | -0.42 | 0.00 | - |
| 12/2023 FY | -0.48 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 128.97K |
| Shares Outstanding | 51.97K |
| Shares Float | 47.25M |
| Trades Count | 342 |
| Dollar Volume | 117.30K |
| Avg. Volume | 271.17K |
| Avg. Weekly Volume | 124.28K |
| Avg. Monthly Volume | 287.37K |
| Avg. Quarterly Volume | 401.84K |
Genprex Inc. (NASDAQ: GNPX) stock closed at 0.9099 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 128.97K shares and market capitalization of 47.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Genprex Inc. CEO is J. Rodney Varner.
The one-year performance of Genprex Inc. stock is -60.04%, while year-to-date (YTD) performance is -37.25%. GNPX stock has a five-year performance of -80.64%. Its 52-week range is between 0.7358 and 2.67, which gives GNPX stock a 52-week price range ratio of 9.00%
Genprex Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 2.50, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.41%, a ROC of -62.47% and a ROE of -62.37%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Genprex Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genprex Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Genprex Inc. is Strong Buy (1), with a target price of $5, which is +449.51% compared to the current price. The earnings rating for Genprex Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Genprex Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Genprex Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.15, ATR14 : 0.09, CCI20 : 1.38, Chaikin Money Flow : -0.22, MACD : -0.10, Money Flow Index : 32.67, ROC : 10.01, RSI : 40.32, STOCH (14,3) : 77.62, STOCH RSI : 0.84, UO : 55.58, Williams %R : -22.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Genprex Inc. in the last 12-months were: Ryan M. Confer (Option Excercise at a value of $1 755)
Genprex Inc.
Genprex Inc is a clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
CEO: J. Rodney Varner
Telephone: (877) 774-4679
Address: 1601 Trinity Street, Building B, Austin 78712-1885, TX, US
Number of employees: 8
